Merck Press Releases - EIN Presswire - Press Release Distribution Service

Published on October 3, 2016 - 14:32 GMT

Merck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of Elimination of River Blindness

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, commends the government of Guatemala on being the fourth country in Latin America to receive World Health Organization (WHO) verification of the …

Distribution channels: Companies

Published on October 3, 2016 - 12:17 GMT

Merck to Present New Data on ZEPATIER™ (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company’s chronic hepatitis C virus (HCV) clinical development programs will be presented at The Liver Meeting …

Distribution channels: Companies

Published on September 29, 2016 - 13:27 GMT

Merck Foundation Grant Expands YMCA’s Diabetes Prevention Program in Five States

KENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation and YMCA of the USA (Y-USA) announced today that the Merck Foundation has provided a grant of $2 million over three years to support efforts to expand the YMCA’s Diabetes Prevention Program (YMCA’s …

Distribution channels: Companies

Published on September 28, 2016 - 10:59 GMT

Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that extensive data on KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, have been accepted for presentation at the European …

Distribution channels: Companies

Published on September 23, 2016 - 12:17 GMT

Merck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 25. …

Distribution channels: Companies

Published on September 20, 2016 - 12:35 GMT

Merck to Host Investor Teleconference to Discuss ESMO 2016 Highlights

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States …

Distribution channels: Companies

Published on September 15, 2016 - 12:47 GMT

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and ...

KENILWORTH, N.J., and NEW YORK, N.Y. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 …

Distribution channels: Companies

Published on September 13, 2016 - 13:27 GMT

Merck Publishes 2015/2016 Global Corporate Responsibility Report

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued its 2015/2016 global corporate responsibility report. The report reflects the company’s performance in the areas of Access to Health, …

Distribution channels: Companies

Published on September 7, 2016 - 10:54 GMT

FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) …

Distribution channels: Companies

Published on September 2, 2016 - 11:08 GMT

Merck Provides Update on Odanacatib Development Program

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it is discontinuing the development of odanacatib, Merck’s investigational cathepsin K inhibitor for osteoporosis, and will not …

Distribution channels: Companies

Published on August 8, 2016 - 21:30 GMT

Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR . C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER™ (elbasvir and …

Distribution channels: Companies

Published on August 5, 2016 - 23:56 GMT

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death …

Distribution channels: Companies

Published on August 5, 2016 - 12:06 GMT

Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MK-1293, an …

Distribution channels: Companies

Published on August 2, 2016 - 21:21 GMT

Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, at a dose of 2 mg/kg every …

Distribution channels: Companies

Published on July 29, 2016 - 10:48 GMT

Merck Announces Second-Quarter 2016 Financial Results

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2016. “Our results this quarter reflect our strategic focus on key launches, including …

Distribution channels: Companies

Published on July 26, 2016 - 17:05 GMT

Merck Announces Fourth-Quarter 2016 Dividend

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the fourth quarter of …

Distribution channels: Companies

Published on July 25, 2016 - 12:23 GMT

Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced two regulatory milestones for the company’s investigational vaccine for Ebola Zaire, V920 (rVSV∆G-ZEBOV-GP, live attenuated): the U.S. …

Distribution channels: Companies

Published on July 22, 2016 - 11:22 GMT

Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced efficacy and safety data in previously untreated adults with HIV-1 infection for the company’s investigational once-daily formulation of …

Distribution channels: Companies

Published on July 21, 2016 - 21:27 GMT

Merck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner topical solution) for Cats and Dogs

MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, today announced the U.S. Food and Drug Administration’s approval of BRAVECTO® (fluralaner topical solution) for both cats and dogs, a …

Distribution channels: Companies

Published on July 21, 2016 - 20:56 GMT

Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said that the U.S. Food and Drug Administration (FDA) has requested the submission of new data and analyses from the MODIFY I and MODIFY II …

Distribution channels: Companies